Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
2'-O-Me-RNA
Human Osteopontin
Protein
18 nM (reported value)
Binding Buffer: PBS (137 nM NaCl, 27 nM KCl, 100 nM Na2HPO4, 2 nM K2HPO4, pH 7.4)
37°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
This aptamer is a modified version of OPN-R3 in which the 2'-F-RNA residues have been replaced with 2'-O-Me RNA. The binding affinity was found to be identical to OPN-R3. The modified aptamer was used in vivo on xenograft mice and was found to decrease tumor growth and metastasis.
Osteopontin (2-O-Me OPN-R3) (ID# 371)
5'mCprGprGpmCpmCprApmCprAprGprAp rApmUprGprAprAprAprAprApmCpmCp mUpmCprApmUpmCprGprApmUprGpmUp mUprGpmCprApmUprAprGpmUpmUprGp 3'
41
13079.35 g/mole
402900 L/(mole·cm)
45.00%
2.48
32.46
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Z Mi et al. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Molecular Therapy 17(2009): 153-161
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.